Evidence map›Paper›PMID 30891153›Full record

ArticleWorld journal of diabetes2019

Screening the RFX6-DNA binding domain for potential genetic variants in patients with type 2 diabetes.

Ismail Sami Mahmoud, Ayat Homsi, Hamzeh J Al-Ameer, Jihad Alzyoud, Mais Darras, Mohammad Al Shhab, Malek Zihlif, Ma'mon M Hatmal, Walhan Alshaer

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ismail Sami MahmoudDepartment of Medical Laboratory Sciences, Faculty of Allied Health Sciences, The Hashemite University, Zarqa 13133, Jordan. ismails@hu.edu.jo.
Ayat HomsiCell Therapy Centre, The University of Jordan, Amman 11942, Jordan.
Hamzeh J Al-AmeerDepartment of Pharmacology, Faculty of Medicine, The University of Jordan, Amman 11942, Jordan.
Jihad AlzyoudDepartment of Medical Laboratory Sciences, Faculty of Allied Health Sciences, The Hashemite University, Zarqa 13133, Jordan.
Mais DarrasDepartment of Medical Laboratory Sciences, Faculty of Allied Health Sciences, The Hashemite University, Zarqa 13133, Jordan.
Mohammad Al ShhabDepartment of Pharmacology, Faculty of Medicine, The University of Jordan, Amman 11942, Jordan.
Malek ZihlifDepartment of Pharmacology, Faculty of Medicine, The University of Jordan, Amman 11942, Jordan.
Ma'mon M HatmalDepartment of Medical Laboratory Sciences, Faculty of Allied Health Sciences, The Hashemite University, Zarqa 13133, Jordan.
Walhan AlshaerCell Therapy Centre, The University of Jordan, Amman 11942, Jordan.
University of Jordan · JOHashemite University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe regulatory factor X6 (RFX6), a member of regulatory factor X family, is known to play a key role in the development and differentiation of pancreatic beta cells as well as insulin production and secretion. However, the potential role of RFX6 in type 2 diabetes (T2D) is still unclear.

aimRecent studies have indicated that RFX6 binding to DNA could be disrupted in diabetes. Therefore, in this study we investigated whether genetic mutations are present in the DNA binding domain of

methodsA cohort of T2D patients was enrolled in this study, and the gene encoding the DNA binding domain of RFX6 was amplified by polymerase chain reaction and then analysed by direct DNA sequencing.

resultsThe DNA sequence analysis revealed the absence of any exonic mutation. However, we have identified a new heterozygous single nucleotide polymorphism (IVS6+31 C>T) in the intronic region of DNA binding domain gene that is present in 9.2% and 8.5% of diabetic and control people, respectively (

conclusionWe report the absence of any significant genetic variant that could affect the function of RFX6-DNA binding domain in T2D.

Indexed as

DiabetesDNA binding domainGenetic variantRegulatory factor X6

Identifiers

PMID30891153
PMCPMC6422854
OpenAlexW2921135333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.